Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients

Allistair A. Abraham, Tami D. John, Michael D. Keller, C. Russell N Cruz, Baheyeldin Salem, Lauren Roesch, Hao Liu, Fahmida Hoq, Bambi J. Grilley, Adrian P. Gee, Hema Dave, David A. Jacobsohn, Robert A. Krance, Elizabeth J. Shpall, Caridad A. Martinez, Patrick J. Hanley, Catherine M. Bollard

Research output: Contribution to journalArticle

Abstract

Adoptive transfer of virus-specific T cells (VSTs) has been shown to be safe and effective in stem cell transplant recipients. However, the lack of virus-experienced T cells in donor cord blood (CB) has prevented the development of ex vivo expanded donor-derived VSTs for recipients of this stem cell source. Here we evaluated the feasibility and safety of ex vivo expansion of CB T cells from the 20% fraction of the CB unit in pediatric patients receiving a single CB transplant (CBT). In 2 clinical trials conducted at 2 separate sites, we manufactured CB-derived multivirus-specific T cells (CB-VSTs) targeting Epstein-Barr virus (EBV), adenovirus, and cytomegalovirus (CMV) for 18 (86%) of 21 patients demonstrating feasibility. Manufacturing for 2 CB-VSTs failed to meet lot release because of insufficient cell recovery, and there was 1 sterility breach during separation of the frozen 20% fraction. Delayed engraftment was not observed in patients who received the remaining 80% fraction for the primary CBT. There was no grade 3 to 4 acute graft-versus-host disease (GVHD) associated with the infusion of CB-VSTs. None of the 7 patients who received CB-VSTs as prophylaxis developed end-organ disease from CMV, EBV, or adenovirus. In 7 patients receiving CB-VSTs for viral reactivation or infection, only 1 patient developed end-organ viral disease, which was in an immune privileged site (CMV retinitis) and occurred after steroid therapy for GVHD. Finally, we demonstrated the long-term persistence of adoptively transferred CB-VSTs using T-cell receptor-Vb clonotype tracking, suggesting that CB-VSTs are a feasible addition to antiviral pharmacotherapy.

Original languageEnglish (US)
Pages (from-to)2057-2068
Number of pages12
JournalBlood Advances
Volume3
Issue number14
DOIs
StatePublished - Jul 23 2019

Fingerprint

Fetal Blood
Viruses
T-Lymphocytes
Safety
Graft vs Host Disease
Cytomegalovirus
Human Herpesvirus 4
Transplants
Adenoviridae
Transplant Recipients
Stem Cells
Tissue Donors
Cytomegalovirus Retinitis
Adoptive Transfer
Virus Diseases
T-Cell Antigen Receptor
Infertility
Antiviral Agents
Blood Cells
Steroids

ASJC Scopus subject areas

  • Hematology

Cite this

Abraham, A. A., John, T. D., Keller, M. D., Russell N Cruz, C., Salem, B., Roesch, L., ... Bollard, C. M. (2019). Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Advances, 3(14), 2057-2068. https://doi.org/10.1182/bloodadvances.2019000201

Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. / Abraham, Allistair A.; John, Tami D.; Keller, Michael D.; Russell N Cruz, C.; Salem, Baheyeldin; Roesch, Lauren; Liu, Hao; Hoq, Fahmida; Grilley, Bambi J.; Gee, Adrian P.; Dave, Hema; Jacobsohn, David A.; Krance, Robert A.; Shpall, Elizabeth J.; Martinez, Caridad A.; Hanley, Patrick J.; Bollard, Catherine M.

In: Blood Advances, Vol. 3, No. 14, 23.07.2019, p. 2057-2068.

Research output: Contribution to journalArticle

Abraham, AA, John, TD, Keller, MD, Russell N Cruz, C, Salem, B, Roesch, L, Liu, H, Hoq, F, Grilley, BJ, Gee, AP, Dave, H, Jacobsohn, DA, Krance, RA, Shpall, EJ, Martinez, CA, Hanley, PJ & Bollard, CM 2019, 'Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients', Blood Advances, vol. 3, no. 14, pp. 2057-2068. https://doi.org/10.1182/bloodadvances.2019000201
Abraham, Allistair A. ; John, Tami D. ; Keller, Michael D. ; Russell N Cruz, C. ; Salem, Baheyeldin ; Roesch, Lauren ; Liu, Hao ; Hoq, Fahmida ; Grilley, Bambi J. ; Gee, Adrian P. ; Dave, Hema ; Jacobsohn, David A. ; Krance, Robert A. ; Shpall, Elizabeth J. ; Martinez, Caridad A. ; Hanley, Patrick J. ; Bollard, Catherine M. / Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. In: Blood Advances. 2019 ; Vol. 3, No. 14. pp. 2057-2068.
@article{6bf9d1432ab644bfb94b4b6d20e88b3a,
title = "Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients",
abstract = "Adoptive transfer of virus-specific T cells (VSTs) has been shown to be safe and effective in stem cell transplant recipients. However, the lack of virus-experienced T cells in donor cord blood (CB) has prevented the development of ex vivo expanded donor-derived VSTs for recipients of this stem cell source. Here we evaluated the feasibility and safety of ex vivo expansion of CB T cells from the 20{\%} fraction of the CB unit in pediatric patients receiving a single CB transplant (CBT). In 2 clinical trials conducted at 2 separate sites, we manufactured CB-derived multivirus-specific T cells (CB-VSTs) targeting Epstein-Barr virus (EBV), adenovirus, and cytomegalovirus (CMV) for 18 (86{\%}) of 21 patients demonstrating feasibility. Manufacturing for 2 CB-VSTs failed to meet lot release because of insufficient cell recovery, and there was 1 sterility breach during separation of the frozen 20{\%} fraction. Delayed engraftment was not observed in patients who received the remaining 80{\%} fraction for the primary CBT. There was no grade 3 to 4 acute graft-versus-host disease (GVHD) associated with the infusion of CB-VSTs. None of the 7 patients who received CB-VSTs as prophylaxis developed end-organ disease from CMV, EBV, or adenovirus. In 7 patients receiving CB-VSTs for viral reactivation or infection, only 1 patient developed end-organ viral disease, which was in an immune privileged site (CMV retinitis) and occurred after steroid therapy for GVHD. Finally, we demonstrated the long-term persistence of adoptively transferred CB-VSTs using T-cell receptor-Vb clonotype tracking, suggesting that CB-VSTs are a feasible addition to antiviral pharmacotherapy.",
author = "Abraham, {Allistair A.} and John, {Tami D.} and Keller, {Michael D.} and {Russell N Cruz}, C. and Baheyeldin Salem and Lauren Roesch and Hao Liu and Fahmida Hoq and Grilley, {Bambi J.} and Gee, {Adrian P.} and Hema Dave and Jacobsohn, {David A.} and Krance, {Robert A.} and Shpall, {Elizabeth J.} and Martinez, {Caridad A.} and Hanley, {Patrick J.} and Bollard, {Catherine M.}",
year = "2019",
month = "7",
day = "23",
doi = "10.1182/bloodadvances.2019000201",
language = "English (US)",
volume = "3",
pages = "2057--2068",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "14",

}

TY - JOUR

T1 - Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients

AU - Abraham, Allistair A.

AU - John, Tami D.

AU - Keller, Michael D.

AU - Russell N Cruz, C.

AU - Salem, Baheyeldin

AU - Roesch, Lauren

AU - Liu, Hao

AU - Hoq, Fahmida

AU - Grilley, Bambi J.

AU - Gee, Adrian P.

AU - Dave, Hema

AU - Jacobsohn, David A.

AU - Krance, Robert A.

AU - Shpall, Elizabeth J.

AU - Martinez, Caridad A.

AU - Hanley, Patrick J.

AU - Bollard, Catherine M.

PY - 2019/7/23

Y1 - 2019/7/23

N2 - Adoptive transfer of virus-specific T cells (VSTs) has been shown to be safe and effective in stem cell transplant recipients. However, the lack of virus-experienced T cells in donor cord blood (CB) has prevented the development of ex vivo expanded donor-derived VSTs for recipients of this stem cell source. Here we evaluated the feasibility and safety of ex vivo expansion of CB T cells from the 20% fraction of the CB unit in pediatric patients receiving a single CB transplant (CBT). In 2 clinical trials conducted at 2 separate sites, we manufactured CB-derived multivirus-specific T cells (CB-VSTs) targeting Epstein-Barr virus (EBV), adenovirus, and cytomegalovirus (CMV) for 18 (86%) of 21 patients demonstrating feasibility. Manufacturing for 2 CB-VSTs failed to meet lot release because of insufficient cell recovery, and there was 1 sterility breach during separation of the frozen 20% fraction. Delayed engraftment was not observed in patients who received the remaining 80% fraction for the primary CBT. There was no grade 3 to 4 acute graft-versus-host disease (GVHD) associated with the infusion of CB-VSTs. None of the 7 patients who received CB-VSTs as prophylaxis developed end-organ disease from CMV, EBV, or adenovirus. In 7 patients receiving CB-VSTs for viral reactivation or infection, only 1 patient developed end-organ viral disease, which was in an immune privileged site (CMV retinitis) and occurred after steroid therapy for GVHD. Finally, we demonstrated the long-term persistence of adoptively transferred CB-VSTs using T-cell receptor-Vb clonotype tracking, suggesting that CB-VSTs are a feasible addition to antiviral pharmacotherapy.

AB - Adoptive transfer of virus-specific T cells (VSTs) has been shown to be safe and effective in stem cell transplant recipients. However, the lack of virus-experienced T cells in donor cord blood (CB) has prevented the development of ex vivo expanded donor-derived VSTs for recipients of this stem cell source. Here we evaluated the feasibility and safety of ex vivo expansion of CB T cells from the 20% fraction of the CB unit in pediatric patients receiving a single CB transplant (CBT). In 2 clinical trials conducted at 2 separate sites, we manufactured CB-derived multivirus-specific T cells (CB-VSTs) targeting Epstein-Barr virus (EBV), adenovirus, and cytomegalovirus (CMV) for 18 (86%) of 21 patients demonstrating feasibility. Manufacturing for 2 CB-VSTs failed to meet lot release because of insufficient cell recovery, and there was 1 sterility breach during separation of the frozen 20% fraction. Delayed engraftment was not observed in patients who received the remaining 80% fraction for the primary CBT. There was no grade 3 to 4 acute graft-versus-host disease (GVHD) associated with the infusion of CB-VSTs. None of the 7 patients who received CB-VSTs as prophylaxis developed end-organ disease from CMV, EBV, or adenovirus. In 7 patients receiving CB-VSTs for viral reactivation or infection, only 1 patient developed end-organ viral disease, which was in an immune privileged site (CMV retinitis) and occurred after steroid therapy for GVHD. Finally, we demonstrated the long-term persistence of adoptively transferred CB-VSTs using T-cell receptor-Vb clonotype tracking, suggesting that CB-VSTs are a feasible addition to antiviral pharmacotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85069650281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069650281&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2019000201

DO - 10.1182/bloodadvances.2019000201

M3 - Article

C2 - 31292125

AN - SCOPUS:85069650281

VL - 3

SP - 2057

EP - 2068

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 14

ER -